318 related articles for article (PubMed ID: 28339282)
21. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.
Tohen M; Jacobs TG; Grundy SL; McElroy SL; Banov MC; Janicak PG; Sanger T; Risser R; Zhang F; Toma V; Francis J; Tollefson GD; Breier A
Arch Gen Psychiatry; 2000 Sep; 57(9):841-9. PubMed ID: 10986547
[TBL] [Abstract][Full Text] [Related]
22. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder.
Frazier JA; Biederman J; Tohen M; Feldman PD; Jacobs TG; Toma V; Rater MA; Tarazi RA; Kim GS; Garfield SB; Sohma M; Gonzalez-Heydrich J; Risser RC; Nowlin ZM
J Child Adolesc Psychopharmacol; 2001; 11(3):239-50. PubMed ID: 11642474
[TBL] [Abstract][Full Text] [Related]
23. Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial.
Yatham LN; Beaulieu S; Schaffer A; Kauer-Sant'Anna M; Kapczinski F; Lafer B; Sharma V; Parikh SV; Daigneault A; Qian H; Bond DJ; Silverstone PH; Walji N; Milev R; Baruch P; da Cunha A; Quevedo J; Dias R; Kunz M; Young LT; Lam RW; Wong H
Mol Psychiatry; 2016 Aug; 21(8):1050-6. PubMed ID: 26460229
[TBL] [Abstract][Full Text] [Related]
24. Variables as mediators or moderators in predicting relapse to any type of mood episode in a bipolar maintenance study.
Tohen M; Wang WV; Leboyer M; Jen KY
J Clin Psychiatry; 2012 Jul; 73(7):e913-7. PubMed ID: 22901362
[TBL] [Abstract][Full Text] [Related]
25. Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study.
Maina G; Albert U; Rosso G; Bogetto F
J Clin Psychiatry; 2008 Apr; 69(4):609-16. PubMed ID: 18294024
[TBL] [Abstract][Full Text] [Related]
26. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
J Affect Disord; 2010 Apr; 122(1-2):27-38. PubMed ID: 20096936
[TBL] [Abstract][Full Text] [Related]
27. A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain.
McElroy SL; Winstanley E; Mori N; Martens B; McCoy J; Moeller D; Guerdjikova AI; Keck PE
J Clin Psychopharmacol; 2012 Apr; 32(2):165-72. PubMed ID: 22367654
[TBL] [Abstract][Full Text] [Related]
28. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.
Tohen M; Greil W; Calabrese JR; Sachs GS; Yatham LN; Oerlinghausen BM; Koukopoulos A; Cassano GB; Grunze H; Licht RW; Dell'Osso L; Evans AR; Risser R; Baker RW; Crane H; Dossenbach MR; Bowden CL
Am J Psychiatry; 2005 Jul; 162(7):1281-90. PubMed ID: 15994710
[TBL] [Abstract][Full Text] [Related]
29. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.
Poyurovsky M; Isaacs I; Fuchs C; Schneidman M; Faragian S; Weizman R; Weizman A
Am J Psychiatry; 2003 Feb; 160(2):297-302. PubMed ID: 12562576
[TBL] [Abstract][Full Text] [Related]
30. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study.
Modabbernia A; Heidari P; Soleimani R; Sobhani A; Roshan ZA; Taslimi S; Ashrafi M; Modabbernia MJ
J Psychiatr Res; 2014 Jun; 53():133-40. PubMed ID: 24607293
[TBL] [Abstract][Full Text] [Related]
31. Olanzapine: in adolescents with schizophrenia or bipolar I disorder.
McCormack PL
CNS Drugs; 2010 May; 24(5):443-52. PubMed ID: 20369908
[TBL] [Abstract][Full Text] [Related]
32. Olanzapine: new indication. Prevention of bipolar disorder: unconvincing trials.
Prescrire Int; 2005 Aug; 14(78):140-2. PubMed ID: 16106596
[TBL] [Abstract][Full Text] [Related]
33. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
[TBL] [Abstract][Full Text] [Related]
34. Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.
Kemp DE; Correll CU; Tohen M; Delbello MP; Ganocy SJ; Findling RL; Chang K
J Child Adolesc Psychopharmacol; 2013 Oct; 23(8):522-30. PubMed ID: 24111982
[TBL] [Abstract][Full Text] [Related]
35. Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data.
Suppes T; Brown E; Schuh LM; Baker RW; Tohen M
J Affect Disord; 2005 Dec; 89(1-3):69-77. PubMed ID: 16253344
[TBL] [Abstract][Full Text] [Related]
36. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study.
Poyurovsky M; Tal V; Maayan R; Gil-Ad I; Fuchs C; Weizman A
Eur Neuropsychopharmacol; 2004 Aug; 14(4):332-6. PubMed ID: 15163444
[TBL] [Abstract][Full Text] [Related]
37. Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination.
Poyurovsky M; Fuchs C; Pashinian A; Levi A; Weizman R; Weizman A
Psychopharmacology (Berl); 2013 Apr; 226(3):615-22. PubMed ID: 23239133
[TBL] [Abstract][Full Text] [Related]
38. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial.
Sachs GS; Vanderburg DG; Karayal ON; Kolluri S; Bachinsky M; Cavus I
J Clin Psychiatry; 2012 Nov; 73(11):1412-9. PubMed ID: 23218157
[TBL] [Abstract][Full Text] [Related]
39. Olanzapine - relapse prevention following mania.
Dando S; Tohen M
J Psychopharmacol; 2006 Mar; 20(2 Suppl):31-8. PubMed ID: 16551670
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial.
Bowden CL; Mosolov S; Hranov L; Chen E; Habil H; Kongsakon R; Manfredi R; Lin HN
Int Clin Psychopharmacol; 2010 Mar; 25(2):60-7. PubMed ID: 20101186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
